Research Advances on Clinical Application of Umbilical Cord Blood Transplantation in the Treatment of Hematological Diseases--Review.
10.19746/j.cnki.issn.1009-2137.2020.03.055
- Author:
Li WANG
1
;
Chao ZHANG
2
;
Cheng-Jun LIU
3
,
4
;
Chun-Ji GAO
4
,
5
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China,Department of Hematology, Laoshan Medical District of No. 971 Hospital of Chinese PLA Nary, Qingdao 266101, Shandong Province, China.
2. Department of Hematology, Laoshan Medical District of No. 971 Hospital of Chinese PLA Nary, Qingdao 266101, Shandong Province, China.
3. Department of Hematology, Laoshan Medical District of No. 971 Hospital of Chinese PLA Nary, Qingdao 266101, Shandong Province, China,E-mail: liuchj@
4. com.
5. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China,E-mail: gaochunji301@
- Publication Type:Journal Article
- MeSH:
Cord Blood Stem Cell Transplantation;
Graft vs Host Disease;
Hematologic Diseases;
Hematopoietic Stem Cell Transplantation;
Humans;
Unrelated Donors
- From:
Journal of Experimental Hematology
2020;28(3):1049-1053
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Umbilical cord blood (UCB) is an alternative source of hematopoietic stem cells (HSCs) for patients who were lack of HLA match related or unrelated donors. Compared with bone marrow and mobilized peripheral blood, UCB has the advantages of easy availability, safety for donors, and low requirement for HLA match between donors and recipients. However, the cell amount in UCB is relatively less, which was associated with increased graft failure, delayed hematologic recovery, immune reconstitution, and higher transplant related mortality after UCB transplantation (UCBT). Double-unit UCB is a straightforward method to augment cell amount in UCB. Compared with single-unit UCBT, double-unit CBT associated with less risk of primary disease relapse and increased incidence rate of graft-versus-host disease (GVHD), but the hematologic recovery and overall survival of recipients were no significantly difference between single and double-unit UCBT. Novel strategies for UCB expansion significantly increased the cell amount in UCB, single-unit expanded UCBT not only increased the sources of UCB, but also decreased the high cost of double-unit UCB. ATG can decrease the risk of graft failure and GVHD rate, but the role of ATG in UCBT is still controversial. Herein, the recent clinical advances on UCBT in the treatment of hematologic diseases are systematically reviewed.
